Clinical trial NCT00783471: Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
Official title: Docetaxel Combined With Pulsatile Erlotinib (Tarceva®) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Advanced Non-Small Cell Lung Cancer
Lead sponsor: Hellenic Cooperative Oncology Group
Sponsor class: OTHER
First posted: 2008-10-31
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating patients with the diagnosis of advanced Non-Small-Lung-Cancer

Detailed description: The combination of chemotherapy \[such as docetaxel\] with continuous administration of targeted drugs which block the molecular machinery of cancer cell growth \[such as erlotinib\] have failed to improve their efficacy over only-chemotherapy in patients with metastatic lung cancer of the non-small cell histology type. It is not yet known whether administering targeted drugs intermittently could result in improved efficacy of the combinations. This is a multicenter randomized Phase II trial aiming to determine the more active dosing sequence between intermittent erlotinib and docetaxel for treating patients with advanced Non-Small-Lung-Cancer.Patients will be randomly assigned to one of two treatment arms: they will receive a 12-days course of erlotinib either before docetaxel \[arm A\] or after docetaxel administration \[arm B\].Treatment will be repeated every 21 days.Patients will be evaluated every 2 cycles (\~6 weeks) for response using RECIST criteria. Those patients achieving stable disease or better will continue therapy up to a total 8 cycles. Those patients experiencing progressive disease will be taken off study. Biopsy material will be assessed for biomarkers.

Eligibility criteria: Inclusion Criteria:

1. Male and female patients aged 18 to 75 years inclusive, with histologically confirmed metastatic NSCLC will be enrolled.
2. Patients must have not been previously treated with anticancer drugs for advanced disease.
3. ECOG performance status of 0 - 1.
4. Life expectancy of at least 12 weeks.
5. Patients must be able to take oral medication.
6. At least 4 weeks since any prior major surgery or extended-field radiotherapy. Patients who, in the opinion of the investigator, have fully recovered from limited surgery or have undergone limited-field radiotherapy within 2 weeks may also be considered eligible for the study
7. Granulocyte count \> 1,500/mm3 and platelet count \> 100,000/mm3. Haemoglobin ³ 9.0g/dl.
8. SGOT (AST) and SGPT (ALT) \< 2,5 x ULN in the absence of liver metastases or up to 5 x ULN in case of liver metastases
9. Alkaline phosphatase (ALP) \< 2,5 x ULN. If alkaline phosphatase is \> 2.5 x ULN, SGOT (AST) and SGPT (ALT) must be \< 1.5 x ULN. If alkaline phosphatase is ³ 2.5 x ULN in the presence of liver metastases, SGOT and SGPT must be \< 5 x ULN
10. Serum creatinine \<= 1.5 ULN or creatinine clearance \> 60 ml/min.
11. Normal serum calcium.
12. For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting Tarceva/placebo treatment.
13. Patients with reproductive potential must use effective contraception.
14. Able to comply with study and follow-up procedures.
15. Written (signed) Informed Consent to participate in the study.
16. Written (signed) Informed Consent for use of tumour samples.
17. Presence of measurable or evaluable disease (lesions that are present but do not fulfil the criteria for measurable disease).
18. Formalin-fixed, paraffin-embedded tumour tissue samples representative of the tumour will be provided to sponsor within 3 weeks of the patient starting chemotherapy

Exclusion Criteria:

1. Prior exposure to agents directed at the HER axis (e.g. gefitinib, cetuximab, trastuzumab).
2. Prior chemotherapy or therapy with systemic anti-neoplastic therapy (e.g., monoclonal antibody therapy) for advanced disease. Prior surgery and/or localised irradiation is permitted.
3. Patients who have undergone complete tumour resection after responding to platinum based chemotherapy.
4. Any unstable systemic disease (including active infections, significant cardiovascular disease, \[including myocardial infarction within the previous year\], any significant hepatic, renal or metabolic disease) metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of study medication(s) or that might affect the interpretation of the results or render the patient at high risk from treatment complications.
5. Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
6. Patients are excluded if they have symptomatic brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation; patients with CNS metastases with evidence of stable disease (clinically stable imaging) and stable neurologic function are allowed to enter the study.
7. Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids are excluded.
8. Any inflammatory changes of the surface of the eye.
9. Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
10. Nursing and/or pregnant women.
11. Hypersensitivity to erlotinib (Tarceva) or to docetaxel or to any of the excipients.

Primary outcomes:
measure: Progression free survival (PFS)
timeFrame: Assessment every 6 weeks
Secondary outcomes:
measure: To compare the Overall Survival (OS),the Objective Response Rate (ORR) and duration of response
timeFrame: Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression
measure: Identify predictive signaling molecules of the EGFR pathway
timeFrame: Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Sotiria Hospital
city: Athens
country: Greece
facility: "Alexandra" Hospital
city: Athens
country: Greece
facility: "Attikon" University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic, Oncology Section
city: Athens
country: Greece
facility: Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology
city: Athens
country: Greece
facility: Hygeia Hospital
city: Ioannina
country: Greece
facility: University General Hospital of Ioannina, Medical Oncology Dept
city: Larissa
country: Greece
facility: Larissa University Hospital
city: Piraeus
country: Greece
facility: Metropolitan Hospital, Second Dept of Medical Oncology
city: Pireaus
country: Greece
facility: Metropolitan Hospital, 1st Dept. of Medical Oncology
city: Rio, Patras
country: Greece
facility: Patras University Hospital, Dept. of Internal Medicine, Oncology Section
city: Thessaloniki
country: Greece
facility: Theagenio Cancer Hospital, 2nd Dept of Medical Oncology
city: Thessaloniki
country: Greece
facility: Theagenio Cancer Hospital, 3rd Dept. of Medical Oncology
city: Thessaloniki
country: Greece
facility: "Papageorgiou" Hospital
Study officials:
affiliation: University of Ioannina Hospital, Medical School
name: Evangelos Briasoulis, MD
role: PRINCIPAL_INVESTIGATOR
References: